-
Photocure divests Metvix to Galderma for EUR 51 million
Photocure ASA has entered into agreements with Galderma S.A., under which Galderma has purchased global rights, assets, and liabilities related to Metvix and Metvixia, as well as the exclusive right to develop new dermatology products based on Photocure's patented substance, MAL.
>> Read more01.10.09 -
New CFO in Navamedic ASA
Torbjörn Sannerstedt has been appointed as the new CFO of Navamedic. Before Navamedic, Torbjörn Sannerstedt held the CFO position at AcadeMedia Company.
>> Read more23.09.09 -
EMEA recommends application from Clavis Pharma
The European Medicines Agency (EMEA) has recommended orphan drug designation to Intravenous CP-4126 for the treatment of pancreatic cancer. Clavis Pharma is currently conducting a Phase II study with Intravenous CP-4126 in patients with pancreatic cancer.
>> Read more14.09.09 -
Algeta signs $800 million agreement with Bayer
Algeta ASA has entered into a global agreement with Bayer for the development and commercialization of Algeta's first in class alpha-pharmaceutical, Alpharadin. Alpharadin is currently being evaluated in a global phase III trial in men with hormone-refractory prostate cancer (HRPC) that has spread to the bone.
>> Read more03.09.09 -
New CEO in Navamedic ASA
Olof Milveden is appointed new CEO of Navamedic ASA.
>> Read more05.05.09 -
World Innovation Summit i Barcelona
EU har annonsert 2009 som "The Year of Creativity and Innovation". Spania (Barcelona) har tatt et initiativ ved å lansere møteplassen (mellom investorer og entreprenører) "HIT Barcelona - World Innovation Summit" fra 17.6 til 19.6.2009 i Barcelona.>> Read more24.04.09 -
BMI granted Incubator Status
Innovation Norway has granted Bio-Medisinsk Innovasjon AS (BMI) Incubator Status. As a result of this, the companies and early commercial projects associated with BMI have access to a larger selection of supportive grants in early stage of company development. ”This is an important addition to our existing solutions for bringing new drugs, diagnostics and medical technology faster to the patients", says Ingrid Alfheim, CEO of BMI.
>> Read more04.03.09 -
U.S. court rules in favour of Biotec Pharmacon ASA
Biotec Pharmacon reports that Biothera has been denied permission to file a motion to reconsider the U.S District Court Order of 28 January, 2009, which largely ruled in Biotec Pharmacon's favour in a patent infringement suit. The Court's decision confirms that all of Biothera's claims under 12 of 14 U.S. patents at issue have been dismissed from the case without even requiring a trial.
>> Read more13.02.09 -
Photocure receives a grant of NOK 4.3 mill
Photocure ASA has been rewarded NOK 4.3 mill (~€ 0.5 mill) over 3 years from the BIA program of the Norwegian Research Counsel (NFR). The BIA program supports highly innovative projects that create value to both the company and society.
>> Read more13.02.09 -
Favourable ruling for Biotec Pharmacon
A decision by the U.S district court judge in Minnesota largely rules in Biotec Pharmacon's favour in the patent infringement suit brought by Biopolymer Engineering.
>> Read more04.02.09
Norwegian Bioindustry Association
Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98